CV Sciences, Inc. (OTCQB: CVSI) announced this morning that the company’s second quarter 2018 revenue is expected to have reached $12.3 million, which is up 203% compared to their second quarter last year. The company owns the well-known hemp derived CBD product brand +CBD oil.
CV Sciences owns their own pharmaceutical drug division that works specifically on the research and development of commercial CBD Products. Their subsidiary +CBD Oil focused on the manufacturing, marketing, and distribution of Cannabidiol based products such as soft gel capsules, powdered capsules, sublingual tinctures, topical and sprays.
In the announcement, CV Sciences indicated that the company has increased their retail store count to 1,968 organic health food stores as of the end of June 2018. By allowing customers to purchase online, as well as, through retail outlets across the country the company has been able to significantly increase its visibility with consumers.
CV Sciences, Inc. currently has a market cap of $234.82m and is trading at 2.769 per share.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…